Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAL003 in hypercholesterolemia and mixed dyslipidemia
NCT07295418Phase 3Completed
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Start
- Oct 2023
- Primary completion
- Apr 2025
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of SAL003 in hypercholesterolemia, mixed dyslipidemia, sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd.. Started Oct 2023; status: completed.
02
Drugs
SAL003
03
Conditions
hypercholesterolemiamixed dyslipidemia
Beyond the preview
Go deeper on NCT07295418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07295418.